Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats

University of Iowa, United States of America
PLoS ONE (Impact Factor: 3.23). 11/2012; 7(11):e50852. DOI: 10.1371/journal.pone.0050852
Source: PubMed


Respiratory Syncytial Virus (RSV) is an important viral agent causing severe respiratory tract disease in infants and children as well as in the elderly and immunocompromised individuals. The lack of a safe and effective RSV vaccine represents a major unmet medical need. RSV fusion (F) surface glycoprotein was modified and cloned into a baculovirus vector for efficient expression in Sf9 insect cells. Recombinant RSV F was glycosylated and cleaved into covalently linked F2 and F1 polypeptides that formed homotrimers. RSV F extracted and purified from insect cell membranes assembled into 40 nm protein nanoparticles composed of multiple RSV F oligomers arranged in the form of rosettes. The immunogenicity and protective efficacy of purified RSV F nanoparticles was compared to live and formalin inactivated RSV in cotton rats. Immunized animals induced neutralizing serum antibodies, inhibited virus replication in the lungs, and had no signs of disease enhancement in the respiratory track of challenged animals. RSV F nanoparticles also induced IgG competitive for binding of palivizumab neutralizing monoclonal antibody to RSV F antigenic site II. Antibodies to this epitope are known to protect against RSV when passively administered in high risk infants. Together these data provide a rational for continued development a recombinant RSV F nanoparticle vaccine candidate.

Download full-text


Available from: David C Flyer, May 28, 2014
22 Reads
  • Source
    • "The utility of SE-UHPLC separations has been realized in many areas of fundamental biochemistry research. In this capacity, these size separations have primarily been used to monitor the purity of laboratory-produced protein-related compounds [77] [78] [79] [80] [81]. In other examples, SE-UHPLC has been used as a purification step to purify cross-linked proteins in the study of cellular processes [82], and has also proved useful in protein-binding studies where differences in hydrodynamic radii between the reactant and the product can be used to advantage [83] [84]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The separation of molecular compounds based on their capacity to access the intra-particle pore volume of chromatographic media, which is dictated by the relative size in solution of those compounds, has been commonly known as size-exclusion chromatography (SEC) or gel-permeation chromatography (GPC). Conventionally, these two terms have been applied to the analysis of biomolecules and polymers, respectively. Over the more than half-a-century history of size-based separations, there has been a series of advancements, starting from the earliest soft-gel particles and culminating within the past few years in the use of sub-2-µm particles in ultra-high-performance liquid chromatography (UHPLC). The intent of this review is to provide a concise synopsis of the advancements of both chromatography columns and instrumentation for protein and polymer size-based separations. Also, this review presents brief summaries of the application of UHPLC technology for these classes of analytes.
    TrAC Trends in Analytical Chemistry 12/2014; 63. DOI:10.1016/j.trac.2014.08.002 · 6.47 Impact Factor
  • Source
    • "Competitive inhibition by cotton rat sera of the binding of palivizumab monoclonal antibody (ASD Specialty Heath Care Inc., Chicago IL) was measured by an ELISA method as previously described [25]. Serum RSV virus neutralization titers were determined as described previously [25] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Post-infectious immunity to respiratory syncytial virus (RSV) infection results in limited protection as evidenced by the high rate of infant hospitalization in the face of high titer, maternally derived RSV-specific antibodies. By contrast, RSV fusion (F) glycoprotein antigenic site II humanized monoclonal antibodies, palivizumab and motavizumab, have been shown to reduce RSV-related hospitalization in infants. Immunogenicity and efficacy studies were conducted in cotton rats comparing a recombinant RSV F nanoparticle vaccine with palivizumab and controlled with live RSV virus intranasal immunization and, formalin inactivated RSV vaccine. Active immunization with RSV F nanoparticle vaccine containing an alum adjuvant induced serum levels of palivizumab competing antibody (PCA) greater than passive administration of 15 mg/kg palivizumab (human prophylactic dose) in cotton rats and neutralized RSV-A and RSV-B viruses. Immunization prevented detectable RSV replication in the lungs and, unlike passive administration of palivizumab, in the nasal passage of challenged cotton rats. Histology of lung tissues following RSV challenge showed no enhanced disease in the vaccinated groups in contrast to formalin inactivated ‘Lot 100’ vaccine. Passive intramuscular administration of RSV F vaccine-induced immune sera one day prior to challenge of cotton rats reduced viral titers by 2 or more log10 virus per gram of lung and nasal tissue and at doses less than palivizumab. A recombinant RSV F nanoparticle vaccine protected lower and upper respiratory tract against both RSV A and B strain infection and induced polyclonal palivizumab competing antibodies similar to but potentially more broadly protective against RSV than palivizumab.
    Vaccine 09/2014; 32(48). DOI:10.1016/j.vaccine.2014.09.030 · 3.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: We performed a Phase 1 randomized, observer-blinded, placebo-controlled trial to evaluate the safety and immunogenicity of a recombinant respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine. Methods: Six formulations with (5, 15, 30 and 60 μg) and without (30 and 60 μg) aluminum phosphate (AdjuPhos) were administered intramuscularly on day 0 and 30 in a dose escalating fashion to healthy adults 18-49 years of age. Solicited and unsolicited events were collected through day 210. Immunogenicity measures taken at day 0, 30 and 60 included RSV A and B microneutralization, anti-F IgG, antigenic site II peptide and palivizumab competitive antibodies. Results: The vaccine was well-tolerated, with no evident dose-related toxicity or attributable SAEs. At day 60 both RSV A and B microneutralization was significantly increased in vaccinees versus placebo. Across all vaccinees there was a 7- to 19-fold increase in the anti-F IgG and a 7- to 24-fold increase in the antigenic site II binding and palivizumab competitive antibodies. Conclusions: The RSV F nanoparticle vaccine candidate was well tolerated without dose-related increases in adverse events. Measures of immunity indicate that neutralization, anti-RSV F IgG titers and palivizumab competing antibodies were induced at levels that have been associated with decreased risk of hospitalization. NCT01290419.
    Vaccine 11/2012; 31(3). DOI:10.1016/j.vaccine.2012.11.009 · 3.62 Impact Factor
Show more